Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Fuji
Deloitte
Chubb
Citi
US Army
Chinese Patent Office
Boehringer Ingelheim
Farmers Insurance
McKesson

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,093,342

« Back to Dashboard

Summary for Patent: 5,093,342
Title: Use of omeprazole as an antimicrobial agent
Abstract:Use of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benz imidazole or a pharmaceutically acceptable salt thereof in the treatment of infectious diseases, especially such caused by Campylobacter pylori.
Inventor(s): Tomoi; Masaaki (Higashi-Osaka, JP), Ikeda; Yoshifumi (Nakatsu, JP), Yokota; Yoshiko (Ibaraki, JP)
Assignee: Aktiebolaget Hassle (Molndal, SE)
Application Number:07/572,951
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 5,093,342

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,093,342

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan1-30311Feb 09, 1989
PCT Information
PCT FiledFebruary 02, 1990PCT Application Number:PCT/SE90/00070
PCT Publication Date:August 23, 1990PCT Publication Number: WO90/09175

International Patents Family Members for US Patent 5,093,342

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 94063 ➤ Subscribe
Australia 5038190 ➤ Subscribe
Australia 626641 ➤ Subscribe
Canada 2025668 ➤ Subscribe
Cyprus 1909 ➤ Subscribe
Germany 69003207 ➤ Subscribe
Denmark 0414847 ➤ Subscribe
European Patent Office 0414847 ➤ Subscribe
Spain 2058892 ➤ Subscribe
Hong Kong 52196 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Teva
Cerilliant
Cantor Fitzgerald
AstraZeneca
Julphar
Cipla
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot